Clinical Trial Update: Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) [Phase 2]

View source ↗

Summary

This Clinical Trials update outlines a Phase 2 study (ReACT 2.0) evaluating risk-adapted therapy guided by circulating tumor HPV DNA profiling in HPV-positive o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING